The agency said it will evaluate whether further regulatory action is needed after investigating the deaths of two patients ...

The U.S. Food and Drug Administration said on Tuesday that it is investigating reports of two deaths due to acute liver ...

Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the best mid cap growth stocks to invest in now. Earlier on June 4, Sarepta ...

Sarepta has issued a safety update regarding Elevidys (delandistrogene moxeparvovec-rokl) following a second reported case of acute liver failure resulting in death.

The Inflation Reduction Act includes an exemption for orphan drugs for a single indication, but experts say this is far from sufficient to maintain momentum in the rare disease space.

Shares in both companies were down following news of the second death, casting fresh safety concerns over Elevidys.

Nicole Verdun, MD, super office director of the FDA’s Office of Therapeutic Products (OTP) and her deputy Rachael Anatol, PhD ...

Wall Street’s major market averages seesawed back and forth on Friday and finished mixed as Federal Reserve Governor ...

Notable research news last week included Sarepta Therapeutics reporting another death associated with a trial of its Duchenne ...

The S&P500 (SP500) closed in the red, with investors keeping a close eye on the escalating tensions in the Middle East. For ...